NCT03711318TerminatedPhase 3
Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
New York State Psychiatric Institute1 site in 1 country8 target enrollmentStarted: November 1, 2018Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Terminated
- Enrollment
- 8
- Locations
- 1
- Primary Endpoint
- Proportion of Heroin-dependent Patients Successfully Inducted Onto Vivitrol
Study Overview
Brief Summary
A short-term treatment with buprenorphine prior to initiating treatment with naltrexone may increase the proportion of heroin-dependent patients successfully inducted onto Vivitrol.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Individuals between the ages of 18-60
- •Meets DSM-5 criteria of current opioid use disorder with six consecutive months of reported heroin use, supported by a positive urine for opiates indicating regular use of heroin
- •Seeking treatment for opioid use disorder with Vivitrol
- •Capable of giving informed consent and complying with study procedures
- •In otherwise good health based on complete medical history and physical examination, laboratory tests, and EKG
- •BMI between 18-40
Exclusion Criteria
- •Reported treatment with methadone in the last 3 months or positive urine toxicology for methadone on the day of consent
- •Maintenance on, or regular use of buprenorphine or other prescription opioids
- •Pregnancy, lactation, or failure in a sexually active woman to use adequate contraceptive methods.
- •Active medical illness which might make participation hazardous, such as untreated hypertension, acute hepatitis with AST or ALT > 3 times normal, AIDS (CD4 count under 200 currently or medically ill with an opportunistic infection), unstable diabetes, cardiovascular disease.
- •Active psychiatric disorder which might interfere with participation or make participation hazardous, including DSM-5 Schizophrenia or any psychotic disorder, severe Major Depressive Disorder, or suicide risk or 1 or more suicide attempts within the past year.
- •Physiologically dependent on alcohol or sedative- hypnotics with impending withdrawal. Other substance use diagnoses are not exclusionary.
- •History of allergic or adverse reaction to buprenorphine, naltrexone, naloxone, clonidine, or clonazepam.
- •Chronic neurocognitive disorder
- •History of accidental drug overdose in the last 3 years as defined as an episode of opioid-induced unconsciousness or incapacitation, whether or not medical treatment was sought or received.
- •Painful medical condition that requires ongoing opioid analgesia or anticipated surgery necessitating opioid medications
- •Fentanyl only use, supported by a urine toxicology that is positive for fentanyl only and negative for all other opioids.
- •Court mandated to treatment
Arms & Interventions
Short-term treatment with buprenorphine
Experimental
Short-term treatment with buprenorphine
Intervention: Buprenorphine/naloxone (Drug)
Outcomes
Primary Outcomes
Proportion of Heroin-dependent Patients Successfully Inducted Onto Vivitrol
Time Frame: 12 weeks
Number of patients who received the first Vivitrol injection among those who initiated the induction
Secondary Outcomes
No secondary outcomes reported
Investigators
Adam Bisaga
Professor of Psychiatry
New York State Psychiatric Institute
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Blockade Efficacy of Buprenorphine/Naloxone For Opioid DependenceOpioid-Related DisordersNCT00134888National Institute on Drug Abuse (NIDA)8
Completed
Phase 1
Nalrexone Facilitated Discontinuation of BuprenorphineStable Opioid DependenceNCT01895036New York State Psychiatric Institute6
Recruiting
Phase 2
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use DisorderOpioid-use DisorderNCT05011266New York State Psychiatric Institute180
Completed
Phase 4
Naltrexone and Bupropion Combination on Obese,Smoking Patients With SchizophreniaObeseCigarette-smokingSchizophreniaNCT02736474Shanghai Mental Health Center22
Completed
Phase 2
Buprenorphine Pharmacology Related to Addiction Treatment - 18Opioid-Related DisordersNCT00000236National Institute on Drug Abuse (NIDA)